

I-BFM COMMITTEE INTERIM MEETING ALL, B&D, GV, RD and SCT COMMITTEES 27-28 January 2025

Individual Committee meetings at a glance

MONDAY 27 JANUARY			
Room name	Oggioni room	Alabastro A room	Alabastro B room
Capacity	200 pax max	120 pax max	68 pax max
8:00-10:00	ALL	B&D + GV Primarily GV agenda	SCT Forum 2 (closed)
10:00-10:30	Coffee break		
10:30-12:30	ALL + ResDis	B&D + GV Primarily B&D agenda (HHD-ALL; HARMONY update; ETV6::RUNX1+CDKN2Adel; BCL2; ABL-class response to chemo/TKI; genetics of blina response)	SCT Forum 2 (closed)
12:30-14:00	Lunch		
14:00-16:00	ResDis + B&D + GV T-ALL, CNS diagnostics, TP53	Breakout Room	SCT SCT outside ALL
16:00-16:30	Coffee break		
16:30-18:30	ALL + B&D + GV predisposition syndromes; FACES	ResDis clinical	SCT Forum 1

TUESDAY 28 JANUARY		
Room name	Oggioni room	Stampa room
Capacity	200 pax max	20 pax max
8:30-10:30	ResDis + B&D + ALL biology and diagnostics in resistant disease	
10:30-11:00	Coffee break	
11:00-12:30	ResDis + B&D + ALL biology and diagnostics in resistant disease	
12:30-14:00	Lunch	
14:00-15:30	ResDis + SCT + ALL CAR T – CAR Task force	Breakout Room
15:30-16:00	Coffee break	
16:00-18:30	ResDis + SCT + ALL CAR T – CAR Task force	TSC meeting Cario/Rizzari

ALL Committee (Oggioni room)

Monday, 08:00 - 10:00 TBD (Chair: André Baruchel)

08:00-08:10: Welcome (**Arndt Borkhardt**)

08:10: Ph+ / ABL-class ALL protocol – update incl. survey on European strategies in the interim phase;
Andrea Biondi

08:30: Initiation of discussion of next Ph+ / ABL class protocol (**Rob Pieters**, Andrea Biondi, Gunnar Cario)

08:50: Overview of Blinatumomab results for non-ABL class ALL (**André Baruchel**)

09:00: Overview of COG/US treatment strategies for non-ABL class ALL in the Blina-Era (**Sarah Tasian**)

09:20: Overview of treatment strategies for non-ABL class ALL in the Blina-Era (**Martin Schrappe**, Inge van der Sluis)

09:40: Replacement of chemotherapy with Blinatumomab at 1st relapse (**David O'Connor**)

09:50: General discussion of immunotherapy for non-ABL class ALL (all)

(will surely be cont. during coffee break)

10.00 - 10:30 COFFEE BREAK

ALL + ResDis Committees (Oggioni room)

Monday, 10:30 -12:30 (Chair: Carmelo Rizzari)

10:30: CNS therapy in the Blina era (**Chris Halsey**)

10:45: Can frontline ALL protocols be harmonized or built with complementarity - pros and cons (**Mats Heyman**, Gunnar Cario, Rob Pieters, Chris Halsey)

11:00: Induction therapy diversities (**Rob Pieters**)

11:15: STFS monitoring across IBFM protocols (**Liv Andres-Jensen**, Kjeld Schmiegelow)

11:35: From basic science to clinical trials incl. pharma interactions illustrated by Lusvertikimab (targeting aberrant IL7 activation) (**Denis Schewe**) – discussions on pharma interactions (**Mats Heyman**)

12:00: Obesity and drug dosing (**Sarah Elitzur**)

12:15: Jordan Society of Pediatric Oncology: ALL therapy and strategies (**Rawad Rihani**)

12.30 - 14:00 LIGHT LUNCH

B&D + GV Committees (room Alabastro A)

Monday, 8:30 - 10:00 – ‘GV oriented’ (Chair: Gianni Cazzaniga)

Screening

- French experience in testing familial ALL cases (hidden heritability) (**H. Cavé**) 10'
- Polish experience on clinically selected ALL patients (**A. Pastorczak**) 10'

Biology

- ETV6 germline variants and hyperdiploidy (**T. Brozou**) 15'
- PAX5 collaborative project: in-vitro data on novel variants (**F. Auer**) 15'
- Comprehensive Genomic Characterization of ATM in pediatric lymphoid malignancies (**S. Junk**) 10'
- Endophilin A2 Deficiency Impairs Antibody Production in Humans (**R. Farah**) 10'

Surveillance indications/guidelines

- general discussion 20'

10.00 - 10:30 COFFEE BREAK

Monday, 10:30 -12:30 – ‘B&D oriented’ (Chair: Jan Zuna)

Updates, new proposals/collaborations, biology and diagnostics
HHD-ALL (**Karin Nebral**, **Andishe Attarbashi**, **Anthony Moorman**)
HARMONY update + MRD implementation (**Anthony Moorman**, **Mirella Ampatzidou**)
ETV6::RUNX1 with CDKN2A deletion (**Mirella Ampatzidou**)
BCL2 vulnerabilities (**Lüder H. Meyer**)
ABL-class response to chemo/TKI (**Judith Boer**)
Genetics of Blina response (**Anthony Moorman**)

12.30 - 14:00 LIGHT LUNCH

SCT Committee (room Alabastro B)

Monday, 8:30 - 10:00 – Forum 2 (closed, for Steering Committee members) (Chair: TBA)

10.00 - 10:30 COFFEE BREAK

Monday, 10:30 -12:30 – Forum 2 (closed, for Steering Committee members) (Chair: TBA)

Forum 2 study, update and acillary studies (Chair: Peter Bader Anita Lawitschka (TBC)

12.30 - 14:00 LIGHT LUNCH

SCT Committee (Alabastro B)

Monday, 14:00 - 16:00 – SCT outside ALL setting (Chairs: S Nucera & K Kalwak)

Single CBT vs Haplo-PTCY in AML (**A Ruggeri or B di Mayo**)

TBI in children from 2 to 4 years of age, an EBMT retrospective study (**K Kalwak**)

Results of haplo HSCT in patients with relapsed or refractory neuroblastoma (**S Corbacioglu**)

Update of the SCRIPT AML study (**K Mellgren**)

Development of 2 different applications for scoring and recoding data from patients presented with GvHD (**S Nucera**)

16.00 - 16:30 COFFEE BREAK

Monday, 16:30 - 18:30 – Forum 1, studies and publications on going/work in progress (Chair: Christina Paters, TBC)

ResDis + B&D + GV (Oggioni room)

Monday, 14:00 - 16:00 – T-ALL, CNS diagnostics, TP53 (Chair: Jan Zuna)

T-ALL biology:

Predictive value of methylation profiles (**Sofie Degerman**)

Predictive value of transcriptomics (**David O'Connor**)

T-ALL: New agents:

One slide of options and discussion (**Andrej Lissat; JPB, Paco Bautista**)

CNS:

ALL novel targets (**Chris Halsey**)

TP53 mutations:

Distributions across subtypes and clinical significance (frontline and relapse) (**Conny Eckert**)

Genetic Determinants of InO Sensitivity in B-ALL (**Carolin Escherich**)

16.00 - 16:30 COFFEE BREAK

ALL + GV + B&D Committees (Oggioni room)

Monday, 16:30 - 18:30 – Title (Chair: TBD)

Overview predisposition syndromes

Proposal on ALL screening - Relevant issues:

- Which genes
- Ethics: which consent, :ncidental/secondary findings

- Clinical approach to patients with A-T and hematological malignancies (**S.Elitzur**)

- BCR::ABL1-positivity at the end of ALL treatment – available data and proposal for data collection (**Jan Zuna**) - 10-15'

ResDis Committee (Alabastro A room)

Monday, 16:30 - 18:30 – Clinical I (Chairs: Francesca Delbufalo, Andrej Lissat)

Clinical trial committee meeting

16:30: HR and Pfizer trial, (**Arend v. Stackelberg**)

16:45: SR trial (**Arend v. Stackelberg**)

17:00: T-ALL trial and Hem-iSmart (**Rohrlich, Lissat**)

17:15: Horizon IntReALL grant WP reports and action points WP1+2 (**Stackelberg**), WP3 (**Bourquin**)

WP4 (**Locatelli**)

17:30: Unpublished research – proposals for ResDis group

Topics proposed by ResDis Com members

New BCL2 inhibitors (**Paco Bautista**) Targeting MYC (Frank van Leeuwen) Dasatinib and biomarkers

(Frederic van Delft)

18:15 Business meeting (**Bourquin**) and confirmation by RD of the nomination to the next chair 2025-2028 (one candidate), renewal of the executive committee (core group to assist the chair), other topics for decision?

Joint Dinner @ il Pianone Restaurant Via al Pianone21, 24129, Bergamo (bus transportation organized, attendance only possible for 151 people, who signed in during registration)

ALL, ResDis and B&D Committees (Oggioni room)

Tuesday, 08:30 - 10:30 TBD (Chair: Jan Zuna, Paco Bautista)

CNS diagnostics

8:30-8:45 CNS diagnostics - Challenges in Harmonization across centers and trial groups, Exploration of Flowcytometry in the relapse Setting (IntReALL) (**Daniel Ederlyi**)

8:45-8:55 CNS diagnostics in ALLtogether, results (**Chris Halsey**)

8:55-9:05 CNS Flowcytometry: different dynamics at relapse (**Kjeld Schmiegelow**)

9:05-9:15 Discussion: CNS flow diagnostics for trials in the relapse setting

9:15-9:30 ALIC overview of the new trials (**Daniel Erdelyi**)

New agents

9:30-9:45 Relevant new agents for R/R ALL (**Paco Bautista**)

9:45-10:00 Phase 1-2 trial on ziftomenib, Experience with revumenib, (**Janine Stutterheim**)

10:00-10:10 HEM-iSMART, potential new arms and additional new trials (**Paco, Andrej**)

10:10-10:20 Results of the VHR InO cohort (**Erica Brivio**)

10:20- 10:30 Discussion

10.30 - 11:00 COFFEE BREAK

Tuesday, 11:00 -12:30 (Chair: Stackelberg, Baruchel)

11:00-11:15 IBFM ITCC DRP study for T-ALL, Bridge to CAR-T for BCP –ALL (**Zurich Team**)

11:15-11:25 BH3 Profiling / ReALL registry (**Pablo Velasco**)

11:25-11:35 Information about TARGET (**Frank van Leeuwen**)

11:35-11:45 Harmonization Registries, Progress with Marvin (**Andrej Lissat, Fabio Steffen**)

11:45-12:00 Registries: Information about discussions FEDRRAL-ILTB; Registry concept (**JPB, Uri**)

12:00-12:15 Discussion Registries (**Stackelberg, Baruchel, Schmiegelow**)

harmonization-reporting-organizational issues- link to study groups- resources

12:15-12:30 AI developments (**Uri Ilan**)

12.30 - 14:00 LIGHT LUNCH

ResDis + SCT Committees (Oggioni room)

Tuesday, 14:00 - 15:30 – CAR T CAR Task Force (Chairs: Franco Locatelli and Jean-Hugues Dalle)

CAR-T trials

14:00 Miltenyi CD19 CART trial (**Linda Hanssens, Franco Locatelli**)

Inclusion criteria, endpoints, potency assay (**Locatelli**)

Protocol, milestones, EMA advice, timelines, Protocol Working Group, Meetings (**Hanssens**)

14:45 ARI-0001- international scaling for licencing – progress, future opportunities with this model for underrepresented countries? (**Rives**)

15:00 T-ALL PEBL CAR CD7 (**Delbufalo**), CD7 UCL (**Robert Chiesa**) CD38 CAR (?) CD1a (**Rives**)

15.30 - 16:00 COFFEE BREAK

Tuesday, 16:00 - 18:30 – CAR T CAR Task Force (Chairs: Rives and Jean-Hugues Dalle)

Interventions with maintenance therapy:

16:00 Endurance study – maintenance for CAR persistence (Sara Gorashian and Rebecca Gardner) presented by **Friso Calkoen**)

16:30 Proposal for a prospective registry on real world experience with maintenance (non-preemptive) post-HSCT and post-CART (**Pablo Velasco**)

17:00 CARs for B-ALL beyond CD19

CART for AML (**Marta Serafini**)

IL18 and CAR-T responses (**Rossig**)

GD2 CAR progress (**Delbufalo**)

Joint Dinner @ La Ripa Restaurant, Via San Vigilio 1, Bergamo (bus transportation organized, attendance only possible for 99 people, who signed in during registration)